Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: NOMID, DIRA, NLRC4-MAS, SAVI, CANDLE
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Breast Cancer
Interventions: Allergen one-port tissue expander placement, AlloX2 two-port tissue expander placement; Device
Lead sponsor: Lesley Wong; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer
Interventions: Broccoli sprout extract, Mango juice; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Carcinoma, Kidney Carcinoma, Carcinoma
Interventions: Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention, Cold Stimulation; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: Contrast Enhanced Cone Beam Breast CT Scan, Contrast Dye, Iodinated; Radiation · Drug
Lead sponsor: Koning Corporation; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Rochester, New York • Knoxville, Tennessee

Conditions: Acne
Interventions: BEAM device; Device
Lead sponsor: Oregon Aesthetic Technologies; Industry
Eligibility: 15 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Miami Beach, Florida • Warren, Michigan • Portland, Oregon

Conditions: Obesity and Overweight, Breast Cancer Survivorship
Interventions: Broccoli microgreen (BMG); Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: vorinostat, laboratory biomarker analysis, biopsy, F-18 16 alpha-fluoroestradiol, positron emission tomography, anastrozole, letrozole, exemestane, gene expression analysis; Drug · Other · Procedure + 2 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Verruca Vulgaris, Molluscum Contagiosum
Interventions: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 4 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: Talazoparib, Sacituzumab Govitecan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 62
States / cities: Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more

Conditions: Breast Cancer
Interventions: Polygenic Risk Score; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 737 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 2 more

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: vinorelbine tartrate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 200
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more

Conditions: Actinic Keratosis, Photodynamic Therapy
Interventions: Celecoxib 200mg, Placebo; Drug
Lead sponsor: Wright State University; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 43
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Venous Ulcer
Interventions: Standard Wound Care, Flexitouch System with Standard Wound Care; Device
Lead sponsor: Tactile Systems Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • College Station, Texas

Conditions: Atopic Dermatitis
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more

Conditions: Breast Cancer
Interventions: Gemcitabine and Capecitabine and Avastin; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Providence, Rhode Island

Conditions: Breast Cancer, Stress Disorders, Post-Traumatic, Depression
Interventions: workbook/journal on coping with breast cancer, supportive expressive group therapy using videoconferencing; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions: Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation; Procedure · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Arcadia, California • Duarte, California • Irvine, California + 4 more

Conditions: Hidradenitis Suppurativa
Interventions: Placebo, LY3041658; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 86
States / cities: Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more

Conditions: Rheumatoid Arthritis
Interventions: PF-06410293, Adalimumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 49
States / cities: Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 43 more

Search by objective public record fields.

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Comparison of One-port and Two-port Tissue Expanders for Breast Reconstruction

Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Cold Atmospheric Plasma Device Extension Study

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study

Vinorelbine in Treating Children With Recurrent or Refractory Cancers

Photodynamic Therapy-Induced Immune Modulation: Part III

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Flexitouch Treatment for Venous Ulcers

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

Expanding Rural Access: Distance Delivery of Support

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).